Department of Neurology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
Department of Neurology, Huzhou Central Hospital, Hangzhou, China.
Eur Neurol. 2022;85(3):186-194. doi: 10.1159/000520443. Epub 2021 Nov 30.
The best management strategy still remains strong controversy for acute nonarteritic central retinal artery occlusion (CRAO). We thus performed a meta-analysis to determine the efficacy of intra-arterial thrombolysis (IAT) for visual improvement according to different times from symptom onset.
We searched EMBASE, PubMed, and Web of Science for relevant studies assessing efficiency of IAT in patients with CRAO compared with standard therapy. Fixed-effects and random-effects models were performed.
Five eligible studies including 459 patients with acute CRAO were pooled in the meta-analysis. In all, 219 (47.7%) received IAT, and the mean time from symptom onset to IAT was 13 h. The pooled analysis demonstrates odds ratio (OR) for the procedure of IAT and any visual improvement to be 1.520 (95% confidence intervals [CIs] 1.258-1.837; p < 0.001). Subgroup analyses further indicated that the CRAO patients who received IAT achieved any visual improvement more easily within 6 h from symptom onset (OR = 1.703, 95% CI 1.219-2.381; p = 0.002), but not those beyond 6 h (OR = 1.260, 95% CI 0.973-1.632; p = 0.080).
Our meta-analysis of available published data supports IAT to be an alternative treatment option for CRAO patients within 6 h from symptom onset.
急性非动脉炎性视网膜中央动脉阻塞(CRAO)的最佳治疗策略仍存在较大争议。因此,我们进行了一项荟萃分析,以确定根据发病后不同时间进行动脉内溶栓(IAT)对视力改善的疗效。
我们检索了 EMBASE、PubMed 和 Web of Science 中评估 IAT 治疗 CRAO 患者与标准治疗相比的疗效的相关研究。采用固定效应模型和随机效应模型进行分析。
共有 5 项符合纳入标准的研究,共纳入 459 例急性 CRAO 患者。其中,219 例(47.7%)接受了 IAT,发病后接受 IAT 的平均时间为 13 小时。荟萃分析显示,IAT 治疗的优势比(OR)和任何视力改善的 OR 分别为 1.520(95%置信区间 [CI] 1.258-1.837;p < 0.001)。亚组分析进一步表明,发病后 6 小时内接受 IAT 的 CRAO 患者更容易获得任何视力改善(OR = 1.703,95%CI 1.219-2.381;p = 0.002),而发病后 6 小时以上接受 IAT 的患者则不然(OR = 1.260,95%CI 0.973-1.632;p = 0.080)。
我们对现有已发表数据的荟萃分析支持在发病后 6 小时内对 CRAO 患者进行 IAT 治疗作为一种替代治疗选择。